Adlai Nortye (NASDAQ:ANL) is one of the tiny stocks that are on fire right now. On April 16, Adlai Nortye entered into a securities purchase agreement for a private placement equity financing/PIPE expected to yield gross proceeds of ~$150 million. The oversubscribed transaction saw significant participation from a broad group of new and existing institutional healthcare investors, including Soleus Capital, Perceptive Advisors, and Cormorant Asset Management.
The company is selling over 11.3 million American Depositary Shares/ADSs for $13.25 per share, matching its closing price on April 15. The capital infusion is earmarked to advance Adlai Nortye’s clinical-stage pipeline, specifically its RAS-targeting therapies and its proprietary next-generation ADC (antibody-drug conjugate) payload platform, RASiCA. These technologies are central to the company’s mission of transforming terminal cancers into manageable chronic conditions.
Jirsak/Shutterstock.com
As part of the agreement, Adlai Nortye (NASDAQ:ANL) committed to filing a registration statement with the SEC to allow for the resale of the ADSs issued in the placement. High-profile firms, including Leerink Partners and Cantor, served as joint placement agents for the deal, underlining the strong market interest in the company’s specialized oncology platform.
Adlai Nortye (NASDAQ:ANL) is a global clinical-stage company developing innovative cancer therapies through R&D centers in the US and China. Its pipeline features RAS-targeting treatments, including the pan-RAS(ON) inhibitor AN9025, and next-gen immunotherapies like the tri-functional fusion protein AN8025 and oral PD-L1 inhibitor AN4005.
While we acknowledge the potential of ANL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
